Radius Health (RDUS) Misses Q1 EPS by 2c, Revenues Miss; Raises FY19 TYMLOS Sales Mid-Point Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Radius Health Announces First Quarter 2019 Operating Results
May 8, 2019 7:57 AM EDTTYMLOS® U.S. net sales were $29.8 million in the first quarter of 2019 doubling over the first quarter of 2018.
TYMLOS continued increasing its share in the U.S. anabolic osteoporosis market capturing an average of 30% total market share and 42% share in new patients in the first quarter of 2019.
Radius expects TYMLOS to assume anabolic market leadership of new patient starts during the second half of 2019, which if achieved, is expected to translate to total TRx market leadership during 2020.
Radius tightens full-year 2019... More
